Objective: Dietary supplements of the adrernocertical hormone dehydroepiandrosterone (DHEA) are widely taken in the hope of staving off the aging process. Potential dangers have not been fully researched, particularly evidence of a correlation between increased serum concentrations of DHEA and higher breast cancer risk in postmenopausal women. Design: The review examines reports of clinical, epidemiological experimental studies for evidence that DHEA may be a factor in promoting the growth of mammary cancer. Biological mechanisms which might be involved are identi®ed. Results: DHEA is reported to inhibit the growth of human mammary cancer cells in vitro and also the growth of chemically-induced mammary cancer in rats. However, growth inhibition occurs only in the presence of high oestrogen concentrations, and growth stimulation occurs in both models in the presence of a low-level oestrogen milieu. Epidemiological studies report a positive correlation between higher serum concentrations of DHEA and increased breast cancer risk in the case of postmenopausal but not premenopausal women.
Introduction
Serum concentrations of the adrenocortical hormone dehydroepiandrosterone (DHEA) and its sulphate (DHEAS) increase progressively after the age of 30 y. DHEA tablets are widely on sale as a dietary supplement, and reports of its effect on experimental animals have encouraged its human use in the belief that it may counteract the manifestations of aging. However, its possible dangers and mechanisms of action are uncertain and the endocrinemetabolic response to DHEA administration differs between men and women (Larkin, 1988) .
Oral doses of 25 ± 100 mg DHEA daily have been given for periods of 3 ± 6 months to healthy age-advanced men and women in small randomised trials (Morales et al, 1994 (Morales et al, , 1998 Khorram et al, 1997; Casson et al, 1998) . Serum concentrations of DHEA rose to levels typical of young adults (Casson et al, 1998; Morales et al, 1998) . Those of testosterone, dihydrotestosterone and androstenediol were increased above young adult levels in women, although not in men. Serum concentrations of insulin-like growth factor 1 (IGF1) were elevated and sex hormone-binding globulin levels in the circulation were reduced in both sexes. Immune activity was activated both in men (Khorram et al, 1997) and women (Morales et al, 1998) while total body mass was increased in women but fat mass decreased in men. The increased IGF1 levels were similar for 50 mg DHEA daily for 3 months to those for 100 mg daily for 6 months (Morales et al, 1998) but no change was found in insulin concentrations.
In experimental animals, pharmacological dosage of DHEA is reported to diminish obesity, reduce insulin resistance and prevent atherosclerosis (Svec, 1997) . Relevant to this review is evidence that the growth of chemically-induced mammary cancer in rats is inhibited by DHEA in the presence of high oestrogen concentrations, but stimulated in a low-level oestrogen milieu (Boccuzzi et al, 1992) . Opposite effects depending on oestrogen concentrations have also been shown by DHEA on human mammary cancer cell cultures in the laboratory (Boccuzzi et al, 1994) .
It is uncertain whether these oestrogen-dependent effects of DHEA on the growth of experimental tumours are relevant to epidemiological ®ndings on the association between breast cancer risk and serum concentrations of DHEA. In postmenopausal cases, six cohort or case-control studies (Gordon et al, 1990; Dorgan et al, 1996; Berrino et al, 1996; Zeleniuch-Jacquotte et al, 1997; Zumoff et al, 1981) have reported a positive association between increased breast cancer risk and higher serum concentrations of either DHEA or DHEAS but this was not con®rmed in two other studies (Barrett-Connor et al, 1990; Bernstein et al, 1990) . In two studies on premenipausal cases, an increased breast cancer risk was associated with a lower serum concentration of DHEAS (Zumoff et al, 1981; Helzlsouer et al, 1992) . Differences in DHEA and DHEAS levels between cases and controls were in most cases relatively small compared to large intersubject variations, whilst the effect of DHEA administration in postmenopausal women is to cause a 2 to 5-fold increase in concentrations (Casson et al, 1998; Morales et al, 1998) .
DHEA and DHEAS are considered together in this review and are referred to as DHEA(S). The serum concentration of DHEAS is up to 500 times higher than that of DHEA. While DHEAS is bound to albumin, DHEA is active at the tissue level where it is metabolised to steroids such as testosterone and oestrogen. The review examines: (a) Possible mechanisms for a promoting role by DHEA(S) in mammary carcinogenesis; (b) Correlation between DHEA and IGF1 bioactivity; and (c) Effect of obesity and nutritional factors on DHEA(S) concentrations.
Possible role for DHEA in mammary carcinogenesis
DHEA is a precursor of several steroid metabolites and is regarded as an androgen because it is metabolised to testosterone. Its effect on the rat mammary gland is predominantly androgenic (Sourla et al, 1998) . Its intermediate metabolite 5-androstenediol can however compete with oestradiol for binding to the oestrogen receptor (Boccuzzi et al, 1994) . It has been postulated that the association between increased breast cancer risk and higher DHEA(S) concentrations in postmenopausal women could result from stimulation of oestrogen receptor protein in mammary epithelium by 5-androstenediol when oestrogen levels are low (Adams, 1992; Ebeling & Koivisto, 1994 ).
An alternative mechanism is suggested (Dorgan et al, 1999) by the ®nding in some of the DHEA epidemiological studies that a higher testosterone concentration is an independent factor in increasing the risk of postmenopausal breast cancer (Dorgan et al, 1996; Berrino et al, 1996) . As noted above, testosterone levels are markedly raised in women taking DHEA as a dietary supplement (Morales et al, 1994 (Morales et al, , 1998 Khorram et al, 1997; Casson et al, 1998) . International studies report that Chinese women show lower mean testosterone concentrations than do Western women and also have a very much lower incidence of breast cancer (Key et al, 1990) .
Mammary tissue can metabolise androgen to oestrogen which may then synergise with local growth factors in stimulating mammary epithelial growth (Lippman et al, 1998) . There is also evidence that androgen competes for oestrogen receptors in human mammary cancer and elicits oestrogenic effects at pharmacological doses (Rochefort & Garcia, 1984) . Androgen receptors have been identi®ed in a high proportion of mammary cancer specimens and it has been postulated that at physiological levels, androgen might occupy the androgen receptor while at higher levels it might occupy the oestrogen receptor in addition (Zava & McGuire, 1978) .
It is uncertain whether the excess testosterone concentrations seen in women after prolonged intake of DHEA are high enough for such an effect but the perimenopausal switch in major sex steroid production from the ovary to the adrenal gland may lead to clonal selection in the mammary epithelium. Overgrowth of androgen-sensitive cells in precancerous breast lesions around the time of menopause may render them more sensitive to androgen stimulation. A higher testosteroneaoestradiol rate is reported in postmenopausal women with breast cancer compared to controls (Secreto et al, 1983) and it is logical to consider a role for oestrogenaandrogen balance rather than oestrogen alone in the promotion of mammary carcinogenesis in postmenopausal women.
The following observations support the hypothesis that increased androgen concentrations lead to clonal selection of androgen-sensitive cells in the mammary epithelium at the time of the menopause: (a) The incidence of oestrogen receptor-positive precancerous lesions falls sharply at the onset of the menopause when oestrogen levels are falling (Nielsen et al, 1987) ; (b) Testosterone at physiological levels has been reported to stimulate the growth of mammary cancer cell lines derived from postmenopausal tumours but not those derived from premenopausal tumours (Simon et al, 1984) ; (c) Response by advanced breast cancer to high dose androgen therapy varies according to a woman's age in relation to the menopause. In a survey of 521 treated cases, objective response to testosterone propionate was seen in 28% of those more than 5 y postmenopausal, in 17% of those who were postmenopausal 1 ± 5 y and in 8.7% of these within a year after the menopause (Cooperative Breast Cancer Group, 1994) .
The mechanism of testosterone-induced regression of postmenopausal breast cancer is uncertain but it is unlikely to be mediated by inhibition of gonadotropin. A study of 22 premenopausal cases of advanced breast cancer treated by high-dose androgen found no evidence of objective response (Stoll, 1972) . Like high-dose oestrogen therapy, the mechanism of high-dose androgen therapy in causing regression of postmenopausal breast cancer is likely to be mediated by sex steroid receptors in the tumour.
Correlation between DHEA and IGF1 bioactivity
Concentrations of DHEA and DHEAS usually decline with advancing age and are correlated with falling IGF1 concentrations (Paolisso et al, 1997) . A rise in the free IGF1 level following DHEA intake (Morales et al, 1994 (Morales et al, , 1998 Khorram et al, 1997; Casson et al, 1998) may have a role in promoting mammary carcinogenesis. Considerable laboratory evidence shows that interaction between IGF1 and the oestrogen receptor is involved in regulating proliferative activity, apoptosis and carcinogenesis in mammary epithelium (Surmacz et al, 1998) . In postmenopausal women, higher serum concentrations of oestrogen are clearly associated with higher breast cancer risk (Berrino et al, 1996; Toniolo et al, 1995) . A synergistic role for IGF1 is suggested by observations that oestrogen-induced proliferation of human breast cancer cells in vitro is increased by overexpression of the IGF1 receptor (Daws et al, 1996) and that IGF1 stimulates oestrogen receptor activity (Lee et al, 1997) .
Breast cancer specimens show a positive correlation between IGF1 receptor and oestrogen receptor expression (Pekonen et al, 1988; Peyrat et al, 1988; Foekens et al, 1989; Papa et al, 1993) (Rocha et al, 1997) . Epidemiological studies on the association between IGF1 activity and breast cancer risk have also been confounded by incomplete knowledge on in vivo proteolysis of IGFBP3 in relation to IGF1 bioactivity (Rocha et al, 1996) . A positive association between free IGF1 concentration and breast cancer risk is shown in 6 out of 9 reported studies (Peyrat et al, 1993 (Peyrat et al, , 1998 Barni et al, 1994; Bruning et al, 1995; Favoni et al, 1995; Del Giudice et al, 1998; Ng et al, 1998; Vadgama et al, 1999) including a prospective study in 397 cases, and of the three studies failing to show a positive association, two showed instead a positive association with IGFBP3 concentrations (Del Guidice et al, 1998; Ng et al, 1998) . Interpretation of these ®ndings awaits further research.
The age distribution of the association with IGF1 level is not consistent in the studies. Of the six studies showing a positive association, four found it to apply both to pre-and postmenopausal cases (Peyrat et al, 1993 (Peyrat et al, , 1998 Barni et al, 1994; Vadgama et al, 1999) while two found it to apply only to premenopausal cases (Bruning et al, 1995; . One of the latter was a prospective study where the menopausal status was de®ned at the time of blood collection . The researchers point out that although risk was not increased in association with higher postmenopausal IGF1 concentrations, a raised IGF1 level before the menopause could well affect the risk of breast cancer after the menopause.
Most of the experimental evidence that the oestrogen receptor interacts with the IFG1 receptor in regulating proliferative activity in breast tissue is based on observations on breast cancer cells (Daws et al, 1996; Lee et al, 1997) . The interaction may however apply also to normal mammary epithelial cells (Pekonen et al, 1988) . A study of normal human breast tissue implanted into the nude mouse has shown upregulation of IGF1 receptor activity following oestradiol treatment (Clarke et al, 1997) . In the presence of oestradiol therefore, overexpression of IGF1 receptor protein might increase oestrogen receptor activity and favour promotion of carcinogenesis which has already been initiated.
Effects of obesity and nutrition
In postmenopausal women, obesity is predominantly abdominal in distribution and is reported to be positively associated with higher serum concentrations of DHEA (Barrett-Connor & Ferrara, 1996; Haffner et al, 1995) . This contrasts with the ®nding in premenopausal women where abdominal obesity is associated with lower DHEA(S) concentrations (Paolisso et al, 1997; De Pergola et al, 1996; Mantzoros et al, 1996) . The reason for the difference is unclear but multiple studies have shown abdominal obesity to be a marker of increased breast cancer risk in postmenopausal women (Stoll, 1996) .
Postmenopausal abdominal obesity is usually associated with hyperinsulinaemia, and various endocrine-metabolic changes may have a role in promoting mammary carcinogenesis. First, oestrogen levels may be increased by higher oestrogen production in the excess fat deposits, and oestrogen bioactivity increased by lower levels of sex hormonebinding globulin (Ballard-Barbash, 1996; Portischman et al, 1996) . Second, free testosterone levels are increased as is also the production of testosterone and dihydrotestosterone (Kirschner et al, 1990) . Third, serum concentrations of free IGF1 are increased and probably mediated by hyperinsulinaemia (Conover et al, 1992) . Dietary supplements of DHEA are followed by marked increase in serum concentrations of both androgen and IGF1, and may further increase breast cancer risk in women showing evidence of abdominal obesity after the menopause.
Evidence to date on the effect of nutrition and diet on DHEA(S) concentrations is limited and inconclusive. Asian women have signi®cantly lower DHEA(S) levels than do Caucasian women, and also a relatively lower incidence of breast cancer especially after the menopause (Adams, 1992; Khaw, 1996) . When they migrate to the USA or Hawaii, both their DHEA(S) levels and also their breast cancer risk are reported to rise. The high soya content of Asian diets is purported to protect against breast cancer and it may be relevant that supplementary soy feeding to premenopausal Western women is reported to reduce DHEA(S) and also oestradiol concentrations (Lu et al, 1996) .
A study on teenage vegetarians in the USA showed higher DHEA levels than in omnivores (Persky et al, 1995) although a high ®bre diet has been reported to reduce breast cancer risk in case-control studies from many countries. Again, a European study showed that a lactovegetarian diet increased DHEA concentrations in healthy young men and women (Remer et al, 1998) . On the other hand, postmenopausal women show no difference in DHEAS concentrations between vegetarian and non-vegetarian women (Barbosa et al, 1990) .
Conclusion
Administration of DHEA has been shown to inhibit the growth of human breast cancer cell xenografts in the nude mouse and on the basis of experimental studies, the National Institutes of Health in the USA are considering a trial of DHEA as a dietary supplement among its phase two chemopreventive trials in breast cancer (Couillard et al, 1998; Kelloff et al, 1997) . The metabolic-endocrine changes observed in recent studies of prolonged DHEA administration to age-advanced individuals would suggest caution in such trials.
DHEA tablets are classed as a dietary supplement and are widely on sale in many western countries without clear evidence of their safety. They are purported to have immunomodulating and antidepressant effects but considerably more clinical evidence is required. The review examines biological mechanisms by which the metabolic changes reported in elderly women might have a role in the late promotion of mammary carcinogenesis. The evidence would suggest caution both in the use of DHEA as an antiaging regimen and also in its proposed trial for breast cancer prevention.
